Pacira BioSciences, Inc. (PCRX) — Cash Flow Reinvestment Rate
Pacira BioSciences, Inc. (PCRX) has a Cash Flow Reinvestment Rate of 0.98x as of March 2026, reinvesting $25.22 Million (capex $2.72 Million plus investments $22.50 Million) from operating cash flow of $25.68 Million. Explore Pacira BioSciences, Inc. capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Pacira BioSciences, Inc. Cash Flow Reinvestment Rate (2014–2025)
Historical reinvestment intensity for Pacira BioSciences, Inc. across 12 annual periods. Also explore PCRX current and non-current assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Pacira BioSciences, Inc. (2014–2025)
Year-by-year capital reinvestment analysis for Pacira BioSciences, Inc.. For live market cap and broader valuation context, see PCRX company net worth.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.97x | $146.85 Million | $151.99 Million | $15.33 Million | ▲ +94.8% |
| 2024 | 0.50x | $93.91 Million | $189.39 Million | $10.64 Million | ▼ -19.7% |
| 2023 | 0.62x | $95.52 Million | $154.65 Million | $15.16 Million | ▼ -64.8% |
| 2022 | 1.76x | $255.26 Million | $145.27 Million | $30.08 Million | ▼ -55.4% |
| 2021 | 3.94x | $494.98 Million | $125.72 Million | $45.87 Million | ▲ +9.3% |
| 2020 | 3.60x | $277.61 Million | $77.03 Million | $37.80 Million | ▲ +2180.7% |
| 2019 | 0.16x | $11.14 Million | $70.52 Million | $10.16 Million | ▼ -86.3% |
| 2018 | 1.16x | $56.45 Million | $48.87 Million | $14.51 Million | ▼ -89.7% |
| 2017 | 11.26x | $200.31 Million | $17.79 Million | $19.27 Million | ▲ +720.9% |
| 2016 | 1.37x | $45.90 Million | $33.45 Million | $24.71 Million | ▼ -42.7% |
| 2015 | 2.39x | $69.43 Million | $29.00 Million | $41.27 Million | ▼ -42.4% |
| 2014 | 4.16x | $105.91 Million | $25.47 Million | $21.89 Million | — |